Skip to content

Study of nucleoside-sparing regimens stopped early due to high failure rates; NRTIs likely to remain therapeutic backbone for the time being

Patients switching from other PIs to unboosted atazanavir maintain viral suppression

Over 40 million now living with HIV worldwide

HIV treatment activism moves into the TB field

New US HIV infections fall between 2001 and 2004, but complex picture emerges

UK HIV patients have high levels of primary drug resistance

Hepatitis C combination therapies in pill form move nearer

HIV epidemic may assist emergence of human 'bird flu' strain, expert speculates

Heart disease `polypill` to be tested in HIV patients